Glycogen synthase kinase-3β (GSK-3β) and its dysregulation in glioblastoma multiforme

Journal of Clinical Neuroscience

Volumn 20, Issue 9, 2013, Pages 1185-1192

  Atkins, R J ^a   Stylli, S S ^a,b   Luwor, R B ^a   Kaye, A H ^a,b   Hovens, C M ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c Australian Prostate Cancer Research Centre at Epworth   (Australia)

Author keywords

Cancer; Glioblastoma multiforme; GSK 3 ; PI3 K; Wnt

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; MYC PROTEIN; PLATELET DERIVED GROWTH FACTOR; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CHEMOSENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

CANCER; GLIOBLASTOMA MULTIFORME; GSK-3Β; PI3-K; WNT;

ANIMALS; BRAIN NEOPLASMS; CARCINOGENESIS; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SIGNAL TRANSDUCTION;

EID: 84883110364     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2013.02.003     Document Type: Review

References (161)

1. A. Jemal, M.M. Center, and C. DeSantis Global patterns of cancer incidence and mortality rates and trends. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research Am Soc Prev Oncol 19 2010 1893 1907
2. P. Kleihues, and L.H. Sobin World Health Organization classification of tumors Cancer 88 2000 2887
3. F.G. Davis, S. Freels, and J. Grutsch Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, epidemiology, and end results (SEER) data, 1973-1991 J Neurosurg 88 1998 1 10
4. J.F. de Groot, K.R. Lamborn, and S.M. Chang Phase II study of aflibercept in recurrent malignant glioma: a North American brain tumor consortium study J Clin Oncol 29 2011 2689 2695
5. B.K. Edwards, M.L. Brown, and P.A. Wingo Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment J Natl Cancer Inst 97 2005 1407 1427
6. C.V. Gopalakrishnan, A. Dhakoji, and S. Nair A retrospective study of primary cerebellar glioblastoma multiforme in adults J Clin Neurosci 19 2012 1684 1688
7. F.M. Iwamoto, K.R. Lamborn, and J.G. Kuhn A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American brain tumor consortium study 03-03 Neuro Oncol 13 2011 509 516
8. X. Ma, Y. Lv, and J. Liu Survival analysis of 205 patients with glioblastoma multiforme: clinical characteristics, treatment and prognosis in China J Clin Neurosci 16 2009 1595 1598
9. S.S. Stylli, M. Howes, and L. MacGregor Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome J Clin Neurosci 11 2004 584 596
10. S.S. Stylli, and A.H. Kaye Photodynamic therapy of cerebral glioma - a review. Part II - clinical studies J Clin Neurosci 13 2006 709 717
11. S.S. Stylli, A.H. Kaye, and L. MacGregor Photodynamic therapy of high grade glioma - long term survival J Clin Neurosci 12 2005 389 398
12. B. Tran, and M.A. Rosenthal Survival comparison between glioblastoma multiforme and other incurable cancers J Clin Neurosci 17 2010 417 421
13. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
14. S. Bao, Q. Wu, and R.E. McLendon Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
15. A. Giese, and M. Westphal Treatment of malignant glioma: a problem beyond the margins of resection J Cancer Res Clin Oncol 127 2001 217 225
16. M.D. Prados, W.K. Yung, and P.Y. Wen Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study Cancer Chemother Pharmacol 61 2008 1059 1067
17. R.J. Atkins, J. Dimou, and L. Paradiso Regulation of glycogen synthase kinase-3 beta (GSK-3beta) by the Akt pathway in gliomas J Clin Neurosci 19 2012 1558 1563
18. Z. Qu, D. Sun, and W. Young Lithium promotes neural precursor cell proliferation: evidence for the involvement of the non-canonical GSK-3beta-NF-AT signaling Cell Biosci 1 2011 18
19. X. Zhang, T. Chen, and J. Zhang Notch1 promotes glioma cell migration and invasion by stimulating beta-catenin and NF-kappaB signaling via AKT activation Cancer Sci 103 2012 181 190
20. S. Korur, R.M. Huber, and B. Sivasankaran GSK3beta regulates differentiation and growth arrest in glioblastoma PLoS ONE 4 2009 e7443
21. C.A. Grimes, and R.S. Jope The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling Prog Neurobiol 65 2001 391 426
22. J.R. Woodgett Molecular cloning and expression of glycogen synthase kinase-3/factor A EMBO J 9 1990 2431 2438
23. K.F. Lau, C.C. Miller, and B.H. Anderton Expression analysis of glycogen synthase kinase-3 in human tissues J Pept Res 54 1999 85 91
24. I. Buch, D. Fishelovitch, and N. London Allosteric regulation of glycogen synthase kinase 3beta: a theoretical study Biochemistry 49 2010 10890 10901
25. R. Dajani, E. Fraser, and S.M. Roe Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition Cell 105 2001 721 732
26. J.A. Diehl, M. Cheng, and M.F. Roussel Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization Genes Dev 12 1998 3499 3511
27. B. Rubinfeld, I. Albert, and E. Porfiri Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly Science 272 1996 1023 1026
28. C. Liu, Y. Li, and M. Semenov Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism Cell 108 2002 837 847
29. G. Wu, and X. He Threonine 41 in beta-catenin serves as a key phosphorylation relay residue in beta-catenin degradation Biochemistry 45 2006 5319 5323
30. H. Aberle, A. Bauer, and J. Stappert Beta-catenin is a target for the ubiquitin-proteasome pathway EMBO J 16 1997 3797 3804
31. K. Orford, C. Crockett, and J.P. Jensen Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin J Biol Chem 272 1997 24735 24738
32. N. Inagaki, K. Chihara, and N. Arimura CRMP-2 induces axons in cultured hippocampal neurons Nat Neurosci 4 2001 781 782
33. T. Yoshimura, Y. Kawano, and N. Arimura GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity Cell 120 2005 137 149
34. Y. Fukata, T.J. Itoh, and T. Kimura CRMP-2 binds to tubulin heterodimers to promote microtubule assembly Nat Cell Biol 4 2002 583 591
35. M.L. Wong, A.H. Kaye, and C.M. Hovens Targeting malignant glioma survival signalling to improve clinical outcomes J Clin Neurosci 14 2007 301 308
36. H. Jiang, W. Guo, and X. Liang Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators Cell 120 2005 123 135
37. T. Nishimura, K. Kato, and T. Yamaguchi Role of the PAR-3-KIF3 complex in the establishment of neuronal polarity Nat Cell Biol 6 2004 328 334
38. S.H. Shi, L.Y. Jan, and Y.N. Jan Hippocampal neuronal polarity specified by spatially localized mPar3/mPar6 and PI 3-kinase activity Cell 112 2003 63 75
39. F.R. Lucas, R.G. Goold, and P.R. Gordon-Weeks Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium J Cell Sci 111 1998 1351 1361
40. J.S. Yu, and S.D. Yang Protein kinase FA/glycogen synthase kinase-3 predominantly phosphorylates the in vivo site Thr97-Pro in brain myelin basic protein: evidence for Thr-Pro and Ser-Arg-X-X-Ser as consensus sequence motifs J Neurochem 62 1994 1596 1603
41. S. Guidato, L.H. Tsai, and J. Woodgett Differential cellular phosphorylation of neurofilament heavy side-arms by glycogen synthase kinase-3 and cyclin-dependent kinase-5 J Neurochem 66 1996 1698 1706
42. J.Z. Wang, Q. Wu, and A. Smith Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase FEBS Lett 436 1998 28 34
43. M. Hong, D.C. Chen, and P.S. Klein Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3 J Biol Chem 272 1997 25326 25332
44. Y.R. Hong, C.H. Chen, and J.H. Chang Cloning and characterization of a novel human ninein protein that interacts with the glycogen synthase kinase 3beta Biochim Biophys Acta 1492 2000 513 516
45. C.V. Dang, L.M. Resar, and E. Emison Function of the c-Myc oncogenic transcription factor Exp Cell Res 253 1999 63 77
46. B.J. Pulverer, C. Fisher, and K. Vousden Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo Oncogene 9 1994 59 70
47. K. Saksela, T.P. Makela, and K. Hughes Activation of protein kinase C increases phosphorylation of the L-myc trans-activator domain at a GSK-3 target site Oncogene 7 1992 347 353
48. M. Henriksson, A. Bakardjiev, and G. Klein Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential Oncogene 8 1993 3199 3209
49. P.S. Knoepfler, and A.M. Kenney Neural precursor cycling at sonic speed: N-Myc pedals, GSK-3 brakes Cell Cycle 5 2006 47 52
50. M. Ozawa, H. Baribault, and R. Kemler The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species EMBO J 8 1989 1711 1717
51. M. Molenaar, M. van de Wetering, and M. Oosterwegel XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos Cell 86 1996 391 399
52. A. Novak, and S. Dedhar Signaling through beta-catenin and Lef/Tcf Cell Mol Life Sci 56 1999 523 537
53. C. Sakanaka, J.B. Weiss, and L.T. Williams Bridging of beta-catenin and glycogen synthase kinase-3beta by axin and inhibition of beta-catenin-mediated transcription Proc Nat Acad Sci USA 95 1998 3020 3023
54. D.A. Cross, D.R. Alessi, and P. Cohen Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B Nature 378 1995 785 789
55. C. Sutherland, I.A. Leighton, and P. Cohen Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling Biochem J 296 1993 15 19
56. K. Inoki, Y. Li, and T. Zhu TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat Cell Biol 4 2002 648 657
57. J.M. Beaulieu, R.R. Gainetdinov, and M.G. Caron Akt/GSK3 signaling in the action of psychotropic drugs Annu Rev Pharmacol Toxicol 49 2009 327 347
58. H. Eldar-Finkelman, G.M. Argast, and O. Foord Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells Proc Nat Acad Sci USA 93 1996 10228 10233
59. W. Fugel, A.E. Oberholzer, and B. Gschloessl 3,6-Diamino-4-(2-halophenyl) -2-benzoylthieno[2,3-b]pyridine-5-carbonitriles are selective inhibitors of plasmodium falciparum glycogen synthase kinase-3 J Med Chem 10;56 2013 264 275
60. C. Morisco, D. Zebrowski, and G. Condorelli The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes J Biol Chem 275 2000 14466 14475
61. A. Riaz, K.S. Zeller, and S. Johansson Receptor-specific mechanisms regulate phosphorylation of AKT at Ser473: role of RICTOR in beta1 integrin-mediated cell survival PLoS ONE 7 2012 e32081
62. D.D. Sarbassov, D.A. Guertin, and S.M. Ali Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
63. X. Hu, P.P. Pandolfi, and Y. Li MTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma Neoplasia 7 2005 356 368
64. D. Aguilar-Morante, J.A. Morales-Garcia, and M. Sanz-SanCristobal Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8 PLoS ONE 5 2010 e13879
65. X. Fang, S.X. Yu, and Y. Lu Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A Proc Nat Acad Sci USA 97 2000 11960 11965
66. N. Goode, K. Hughes, and J.R. Woodgett Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes J Biol Chem 267 1992 16878 16882
67. G.N. Bijur, P. De Sarno, and R.S. Jope Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium J Biol Chem 275 2000 7583 7590
68. T. Zarubin, and J. Han Activation and signaling of the p38 MAP kinase pathway Cell Res 15 2005 11 18
69. T.M. Thornton, G. Pedraza-Alva, and B. Deng Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation Science 320 2008 667 670
70. A. Cole, S. Frame, and P. Cohen Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event Biochem J 377 2004 249 255
71. E. ter Haar, J.T. Coll, and D.A. Austen Structure of GSK3beta reveals a primed phosphorylation mechanism Nat Struct Biol 8 2001 593 596
72. J.A. Hartigan, W.C. Xiong, and G.V. Johnson Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2 Biochem Biophys Res Commun 284 2001 485 489
73. M. Lesort, R.S. Jope, and G.V. Johnson Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase J Neurochem 72 1999 576 584
74. R.V. Bhat, J. Shanley, and M.P. Correll Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration Proc Nat Acad Sci USA 97 2000 11074 11079
75. J.T. Ayala-Sumuano, C. Velez-Delvalle, and A. Beltran-Langarica Srebf1a is a key regulator of transcriptional control for adipogenesis Sci Rep 1 2011 178
76. A. Takashima, T. Honda, and K. Yasutake Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons Neurosci Res 31 1998 317 323
77. K. Ishiguro, A. Shiratsuchi, and S. Sato Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments FEBS Lett 325 1993 167 172
78. M. Townsend, T. Mehta, and D.J. Selkoe Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway J Biol Chem 282 2007 33305 33312
79. X. Guo, A. Ramirez, and D.S. Waddell Axin and GSK3- control Smad3 protein stability and modulate TGF- signaling Genes Dev 22 2008 106 120
80. R. van Amerongen, and A. Berns Re-evaluating the role of Frat in Wnt-signal transduction Cell Cycle 4 2005 1065 1072
81. J. Behrens, B.A. Jerchow, and M. Wurtele Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta Science 280 1998 596 599
82. H. Yamamoto, S. Kishida, and M. Kishida Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability J Biol Chem 274 1999 10681 10684
83. C. Yost, G.H. Farr 3rd, and S.B. Pierce GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis Cell 93 1998 1031 1041
84. G.H. Farr 3rd, D.M. Ferkey, and C. Yost Interaction among GSK-3, GBP, axin, and APC in Xenopus axis specification J Cell Biol 148 2000 691 702
85. R. van Amerongen, M.C. Nawijn, and J.P. Lambooij Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways Oncogene 29 2010 93 104
86. M.J. Hart, R. De los Santos, and I.N. Albert Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta Curr Biol 8 1998 573 581
87. C.M. Hedgepeth, M.A. Deardorff, and K. Rankin Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin Mol Cell Biol 19 1999 7147 7157
88. V.W. Ding, R.H. Chen, and F. McCormick Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling J Biol Chem 275 2000 32475 32481
89. P.S. Klein, and D.A. Melton A molecular mechanism for the effect of lithium on development Proc Nat Acad Sci USA 93 1996 8455 8459
90. S.P. Davies, H. Reddy, and M. Caivano Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem J 351 2000 95 105
91. V. Stambolic, L. Ruel, and J.R. Woodgett Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells Curr Biol 6 1996 1664 1668
92. W.J. Ryves, and A.J. Harwood Lithium inhibits glycogen synthase kinase-3 by competition for magnesium Biochem Biophys Res Commun 280 2001 720 725
93. R.S. Jope Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes Trends Pharmacol Sci 24 2003 441 443
94. E. Chalecka-Franaszek, and D.M. Chuang Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons Proc Nat Acad Sci USA 96 1999 8745 8750
95. P. De Sarno, X. Li, and R.S. Jope Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium Neuropharmacology 43 2002 1158 1164
96. F. Vidal, W.M. de Araujo, and A.L. Cruz Lithium reduces tumorigenic potential in response to EGF signaling in human colorectal cancer cells Int J Oncol 38 2011 1365 1373
97. A. Sun, I. Shanmugam, and J. Song Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer Prostate 67 2007 976 988
98. J.S. Wang, C.L. Wang, and J.F. Wen Lithium inhibits proliferation of human esophageal cancer cell line Eca-109 by inducing a G2/M cell cycle arrest World J Gastroenterol 14 2008 3982 3989
99. M.O. Nowicki, N. Dmitrieva, and A.M. Stein Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3 Neuro Oncol 10 2008 690 699
100. D. Voskas, L.S. Ling, and J.R. Woodgett Does GSK-3 provide a shortcut for PI3K activation of Wnt signalling? F1000 Biol Rep 2 2010 82
101. X. Zeng, H. Huang, and K. Tamai Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions Development 135 2008 367 375
102. G. Davidson, W. Wu, and J. Shen Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction Nature 438 2005 867 872
103. X. Zeng, K. Tamai, and B. Doble A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation Nature 438 2005 873 877
104. S. Piao, S.H. Lee, and H. Kim Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling PLoS ONE 3 2008 e4046
105. G. Wu, and H. Huang Garcia Abreu J, et al. Inhibition of GSK3 phosphorylation of beta-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6 PLoS ONE 4 2009 e4926
106. K. Tamai, X. Zeng, and C. Liu A mechanism for Wnt coreceptor activation Mol Cell 13 2004 149 156
107. M. Peifer, and P. Polakis Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus Science 287 2000 1606 1609
108. J. Behrens, J.P. von Kries, and M. Kuhl Functional interaction of beta-catenin with the transcription factor LEF-1 Nature 382 1996 638 642
109. E. Brunner, O. Peter, and L. Schweizer Pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in Drosophila Nature 385 1997 829 833
110. J. Riese, X. Yu, and A. Munnerlyn LEF-1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic Cell 88 1997 777 787
111. T.C. He, A.B. Sparks, and C. Rago Identification of c-MYC as a target of the APC pathway Science 281 1998 1509 1512
112. O. Tetsu, and F. McCormick Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells Nature 398 1999 422 426
113. A. Gong, and S. Huang FoxM1 and Wnt/beta-Catenin signaling in Glioma stem cells Cancer Res 72 2012 5658 5662
114. B.W. Doble, S. Patel, and G.A. Wood Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines Dev Cell 12 2007 957 971
115. S.S. Ng, T. Mahmoudi, and E. Danenberg Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade J Biol Chem 284 2009 35308 35313
116. H. McNeill, and J.R. Woodgett When pathways collide: collaboration and connivance among signalling proteins in development Nat Rev Mol Cell Biol 11 2010 404 413
117. B.W. Doble, and J.R. Woodgett GSK-3: tricks of the trade for a multi-tasking kinase J Cell Sci 116 2003 1175 1186
118. N.H. Rekers, P. Sminia, and G.J. Peters Towards tailored therapy of glioblastoma multiforme J Chemother 23 2011 187 199
119. E.J. McManus, K. Sakamoto, and L.J. Armit Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis EMBO J 24 2005 1571 1583
120. S.H. Shi, T. Cheng, and L.Y. Jan APC and GSK-3beta are involved in mPar3 targeting to the nascent axon and establishment of neuronal polarity Curr Biol 14 2004 2025 2032
121. C.R. Beals, C.M. Sheridan, and C.W. Turck Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3 Science 275 1997 1930 1934
122. B.J. Eickholt, F.S. Walsh, and P. Doherty An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling J Cell Biol 157 2002 211 217
123. E.M. Hur, and F.Q. Zhou GSK3 signalling in neural development Nat Rev Neurosci 11 2010 539 551
124. E. Siegfried, L.A. Perkins, and T.M. Capaci Putative protein kinase product of the Drosophila segment-polarity gene zeste-white3 Nature 345 1990 825 829
125. F.Q. Zhou, and W.D. Snider Cell biology. GSK-3beta and microtubule assembly in axons Science 308 2005 211 214
126. D.A. Linseman, B.D. Butts, and T.A. Precht Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis J Neurosci 24 2004 9993 10002
127. C.H. Heldin Protein tyrosine kinase receptors Cancer Surv 27 1996 7 24
128. B. Westermark, C.H. Heldin, and M. Nister Platelet-derived growth factor in human glioma Glia 15 1995 257 263
129. F.G. Barker 2nd, M.L. Simmons, and S.M. Chang EGFR overexpression and radiation response in glioblastoma multiforme Int J Radiat Oncol Biol Phys 51 2001 410 418
130. K.A. McDowell, G.J. Riggins, and G.L. Gallia Targeting the AKT Pathway in Glioblastoma Curr Pharm Des 17 2011 2411 2420
131. A. Aguirre, T.A. Rizvi, and N. Ratner Overexpression of the epidermal growth factor receptor confers migratory properties to nonmigratory postnatal neural progenitors J Neurosci 25 2005 11092 11106
132. D. Ciznadija, Y. Liu, and S.M. Pyonteck CyclinD1 and cdk4 mediate development of neurologically destructive oligodendroglioma Cancer Res 71 2011 6174 6183
133. A.I. Willis, S. Fuse, and X.J. Wang Inhibition of phosphatidylinositol 3-kinase and protein kinase C attenuates extracellular matrix protein-induced vascular smooth muscle cell chemotaxis J Vasc Surg 31 2000 1160 1167
134. F.J. Swartling, M. Ferletta, and M. Kastemar Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines Oncogene 28 2009 3121 3131
135. B. Qiu, D. Zhang, and J. Tao Human brain glioma stem cells are more invasive than their differentiated progeny cells in vitro J Clin Neurosci 19 2012 130 134
136. J. Hu, M. Jo, and W.K. Cavenee Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells Proc Nat Acad Sci USA 108 2011 15984 15989
137. R. Nishikawa, X.D. Ji, and R.C. Harmon A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proc Nat Acad Sci USA 91 1994 7727 7731
138. M. Nagane, F. Coufal, and H. Lin A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis Cancer Res 56 1996 5079 5086
139. H.K. Gan, A.H. Kaye, and R.B. Luwor The EGFRvIII variant in glioblastoma multiforme J Clin Neurosci 16 2009 748 754
140. B.M. Howard, D.B. Gursel, and A.M. Bleau EGFR signaling is differentially activated in patient-derived glioblastoma stem cells J Exp Therapeut Oncol 8 2010 247 260
141. E.A. Maher, F.B. Furnari, and R.M. Bachoo Malignant glioma: genetics and biology of a grave matter Genes Dev 15 2001 1311 1333
142. A. Sehgal Molecular changes during the genesis of human gliomas Semin Surg Oncol 14 1998 3 12
143. S. Kotliarova, S. Pastorino, and L.C. Kovell Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation Cancer Res 68 2008 6643 6651
144. D.R. Laks, M. Masterman-Smith, and K. Visnyei Neurosphere formation is an independent predictor of clinical outcome in malignant glioma Stem Cells 27 2009 980 987
145. L. Wang, Z. Liu, and S. Balivada Interleukin-1beta and transforming growth factor-beta cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells Stem Cell Res Ther 3 2012 5
146. S. Gotze, M. Wolter, and G. Reifenberger Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas Int J Cancer (J Int Du Cancer) 126 2010 2584 2593
147. K. Miyashita, K. Kawakami, and M. Nakada Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma Clin Cancer Res 15 2009 887 897
148. M. Takkunen, M. Hukkanen, and M. Liljestrom Podosome-like structures of non-invasive carcinoma cells are replaced in epithelial-mesenchymal transition by actin comet-embedded invadopodia J Cell Mol Med 14 2010 1569 1593
149. S.S. Stylli, A.H. Kaye, and P. Lock Invadopodia: at the cutting edge of tumour invasion Journal Clin Neurosci 15 2008 725 737
150. S.S. Stylli, I. ST, and A.H. Kaye Prognostic significance of Tks5 expression in gliomas J Clin Neurosci 19 2012 436 442
151. R.H. Zurawel, S.A. Chiappa, and C. Allen Sporadic medulloblastomas contain oncogenic beta-catenin mutations Cancer Res 58 1998 896 899
152. S.R. Hamilton, B. Liu, and R.E. Parsons The molecular basis of Turcot's syndrome N Engl J Med 332 1995 839 847
153. M.F. Kielman, M. Rindapaa, and C. Gaspar Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling Nat Genet 32 2002 594 605
154. R.J. Ward, L. Lee, and K. Graham Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma Cancer Res 69 2009 4682 4690
155. L. Padovani, M.P. Sunyach, and D. Perol Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults Int J Radiat Oncol Biol Phys 68 2007 433 440
156. A.M. Rulseh, J.I. Keller, and J. Klener Long-term survival of patients suffering from glioblastoma multiforme treated with tumortreating fields World J Surg Oncol 10 2012 220
157. S. Ananda, A.K. Nowak, and L. Cher Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy J Clin Neurosci 18 2011 1444 1448
158. A.B. Hjelmeland, Q. Wu, and S. Wickman Targeting A20 decreases glioma stem cell survival and tumor growth PLoS Biol 8 2010 e1000319
159. Y. Cohen, A. Chetrit, and Y. Cohen Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment Med Oncol 15 1998 32 36
160. R. Li, S. Erdamar, and H. Dai Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer Anticancer Res. 29 2009 2077 2081
161. H. Goto, K. Kawano, and I. Kobayashi Expression of cyclin D1 and GSK-3beta and their predictive value of prognosis in squamous cell carcinomas of the tongue Oral Oncol. 38 2002 549 556